OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31

OCULAR THERAPEUTIX, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$6.29−0.58 (-8.44%)

Close on Oct 19, 2026

Market cap: $1.41B
P/E (TTM): –
Dividend yield: –

OCULAR THERAPEUTIX, INC balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Cash & Equivalents	737	394	196	104	166	230	56	61	42	35	31	37	18	24	5.33
Short-Term Investments	–	–	–	–	–	–	–	–	–	35	74	37	0	–	–
Cash & Short-Term Investments	737	394	196	104	166	230	56	61	42	70	105	75	18	24	5.33
Receivables	31	32	26	21	21	12	2.55	0.20	0.23	0.25	0.19	0.33	0.25	–	–
Inventory	3.56	3.04	2.31	1.97	1.25	1.20	0.95	0.22	0.12	0.11	0.13	0.13	0	–	–
Prepaid Expenses & Other	11	13	7.79	4.03	4.75	4.65	2.23	1.71	1.45	1.39	1.59	0.89	0.24	–	–
Total Current Assets	782	441	232	130	191	246	60	56	43	70	107	76	18	–	–
Property, Plant & Equipment	20	9.39	12	9.86	6.96	8.10	10	10	10	3.31	3.10	1.78	0.90	–	–
Gross Property, Plant & Equipment	47	33	32	27	22	21	20	18	16	7.13	6.03	4.00	2.58	–	–
Accumulated Depreciation	-28	-24	-20	-17	-15	-13	-10	-7.63	-5.34	-3.82	-2.94	-2.22	-1.68	–	–
Operating Lease Right-of-Use Assets	4.64	5.95	6.47	8.04	4.87	5.84	6.66	–	–	–	–	–	–	–	–
Total Assets	808	458	252	149	205	262	79	73	55	75	110	78	19	–	–
Accounts Payable	4.15	4.18	4.39	5.12	4.59	2.71	3.27	2.97	3.57	2.12	1.96	1.32	0.55	–	–
Accrued Expenses	44	35	29	24	20	14	7.64	6.19	4.31	4.64	3.38	3.02	0.74	–	–
Current Portion of Leases	2.82	1.93	1.59	1.60	1.62	1.36	1.13	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	0.13	0.26	0.58	–	–	–	–	–	–	0.04	0.19	0.25	–	–
Total Current Liabilities	51	41	35	31	26	27	12	9.16	13	8.30	5.38	5.87	3.34	–	–
Long-Term Debt	71	69	66	25	25	17	25	25	12	14	15	14	0.65	–	–
Long-Term Leases	2.82	5.35	6.88	8.68	5.92	7.55	8.91	–	–	–	–	–	–	–	–
Operating Lease Liabilities	5.63	7.28	8.46	10	7.55	8.91	10	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	0.89	0.14	0.11	0.09	–	–	–	3.22	–	–	–	–	–	–	–
Total Liabilities	154	143	161	114	117	186	82	37	29	23	21	19	4.27	–	–
Total Debt	71	69	66	25	25	17	25	25	12	14	15	14	0.65	–	–
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	–	–	–
Additional Paid-In Capital	1,811	1,206	789	652	634	615	380	333	263	226	219	148	1.31	–	–
Retained Earnings	-1,157	-891	-698	-617	-546	-539	-384	-297	-237	-174	-129	-89	-61	–	–
Comprehensive Income & Other	–	–	–	–	–	–	–	–	–	-0.01	-0.07	–	–	–	–
Shareholders' Equity	654	315	91	35	88	76	-3.63	36	26	52	90	59	-59	-47	-33
Total Equity	654	315	91	35	88	76	-3.63	36	26	52	90	59	-59	-47	-33
Total Liabilities & Equity	808	458	252	149	205	262	79	73	55	75	110	78	19	–	–
Shares Outstanding(shares)	216	158	115	77	77	76	50	42	30	25	25	21	2.68	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 87.1%
Operating margin: -603.0%
Net margin: -579.1%
Return on equity, FY2025: -54.9%

Financial strength

Current ratio: 13.11
Debt to equity: 0.14
Debt to assets: 10.8%
Cash to current liabilities: 1217.4%

Valuation

P/E ratio: –
Price to sales: 27.18
Price to book: 2.72
Dividend yield: –